Our letter to EMA to support the evaluation of the triple combination of CFTR modulators

On behalf of the 48 national Associations in Europe, representing people with CF and their families, CF Europe has sent a letter to the Chair and the Rapporteurs at EMA in charge of evaluating of the novel triple combination for the treatment of cystic fibrosis. Our objective is to play a role in accelerating access to new treatments for all the patients, by expressing our willingness and availability to collaborate with the EMA whenever our expertise and experience could be useful.

You can find the letter here: 2020-02-06_triple combination_letter to EMA



‹ Terug

Contact information

Subscribe to newsletter